MASLD: understanding metabolic fatty liver disease

# MASLD: understanding metabolic fatty liver disease

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is the newer name for most fatty liver linked with excess weight, type 2 diabetes, abnormal lipids, high blood pressure, or other metabolic risk. The name focuses attention on the underlying metabolic health rather than blame. Most people feel well, so risk assessment cannot rely on symptoms.

Fat is common; fibrosis predicts risk

Ultrasound may show liver fat, but the most important long-term question is whether scar tissue, called fibrosis, is developing. A minority progress to steatohepatitis, advanced fibrosis, cirrhosis, or liver cancer. Cardiovascular disease remains a major health risk, so care includes blood pressure, diabetes, cholesterol, smoking, sleep apnoea, and physical activity—not the liver alone.

Diagnosis and FIB-4

The clinician excludes other causes and reviews alcohol exposure and medicines. Routine liver enzymes can be normal despite significant disease. FIB-4 uses age, AST, ALT, and platelet count to identify people unlikely to have advanced fibrosis and those needing a second assessment. Its thresholds need caution in younger and older adults and during acute illness; it is a triage tool, not a diagnosis by itself.

Elastography and specialist review

Transient elastography estimates liver stiffness and can refine fibrosis risk after FIB-4. Results can be influenced by inflammation, congestion, recent food, and technical factors, so context matters. Higher or indeterminate values, persistent enzyme elevation, or clinical signs of advanced disease prompt specialist assessment. Liver biopsy is reserved for selected cases when uncertainty would change management.

Treatment targets

A sustained loss of about 5% body weight can reduce liver fat; 7–10% may improve inflammation, and greater loss can improve fibrosis for some people. The method should be safe and maintainable: Mediterranean-style eating, fewer sugary drinks and ultra-processed foods, resistance plus aerobic exercise, and treatment of diabetes or obesity when indicated. Exercise benefits the liver even before major weight loss.

What changed in the new names

The umbrella term steatotic liver disease describes excess liver fat. MASLD applies when steatosis occurs with at least one cardiometabolic risk factor, while MASH describes MASLD with liver-cell injury and inflammation. A separate MetALD category recognises metabolic disease combined with alcohol exposure above the MASLD range, and other causes retain their own labels. The terminology is intended to be less stigmatising and more biologically useful than ‘non-alcoholic fatty liver disease’. It does not mean alcohol has become irrelevant; an accurate drinking history remains part of every assessment.

Metabolic risks often travel together

Type 2 diabetes, central weight gain, high triglycerides, low HDL cholesterol, raised blood pressure, and impaired glucose regulation increase MASLD risk. Obstructive sleep apnoea, polycystic ovary syndrome, inactivity, and some genetic backgrounds can add risk. Lean people may also develop significant disease, so appearance alone is unreliable. Cardiovascular events are a leading cause of illness and death in MASLD, making blood pressure, lipid treatment, diabetes care, smoking cessation, sleep, and exercise as important as liver tests. Family history of cirrhosis or liver cancer should be mentioned.

Understanding a FIB-4 result

FIB-4 combines age with AST, ALT, and platelet count. A low result in the appropriate age group makes advanced fibrosis less likely and often supports follow-up in primary or routine care. An indeterminate or high result does not diagnose cirrhosis; it signals the need for a second-stage test such as elastography or a specialist pathway. The score is less reliable under age 35, may overestimate risk over 65 unless age-adjusted thresholds are used, and should not be calculated during an acute illness that temporarily changes enzymes or platelets.

Alcohol and medicines

People with MASLD should discuss alcohol honestly in standard drink units because metabolic and alcohol-related injury can reinforce each other. Advanced fibrosis or cirrhosis usually warrants avoiding alcohol; for lower-risk disease, the safest individual limit depends on comorbidity and guideline context. Statins are generally used when indicated for cardiovascular risk and are not routinely withheld merely because MASLD is present. Diabetes and obesity medicines, including incretin-based therapies, may improve weight and metabolic health, while liver-targeted medicines are reserved for defined patients under specialist guidance. Unregulated ‘liver detox’ supplements can cause injury.

Myths and facts

Only people with obesity develop fatty liver

Lean people can develop MASLD, especially with diabetes or genetic risk.

A detox cleans liver fat

No cleanse replaces weight, metabolic, and alcohol assessment.

Normal ALT means a healthy liver

Fibrosis can exist with enzymes in the laboratory range.

When to see a doctor

Most MASLD follow-up is planned rather than urgent, but persistent enzyme elevation, an indeterminate or raised fibrosis assessment, low platelets, or signs of advanced disease should prompt specialist review. New jaundice, increasing abdominal swelling, vomiting blood, black stool, confusion, unusual sleepiness, or sudden leg swelling can indicate decompensated liver disease and needs urgent evaluation. People with diabetes, several metabolic risks, or a first-degree relative with cirrhosis should not wait for pain: fibrosis can progress silently, so ask when blood tests and non-invasive fibrosis assessment should be repeated.

Practical checklist

• Check waist, blood pressure, glucose/HbA1c, and lipids.
• Ask whether your FIB-4 is interpretable and if elastography is needed.
• Aim first for a sustainable 5% weight reduction if advised.
• Avoid unregulated supplements that may themselves injure the liver.

A next step

You can book a consultation to discuss your questions.

Fixed medical disclaimer: This content is for general education and does not replace individual diagnosis or treatment by a qualified clinician. In an emergency, contact local emergency services immediately.

References

• EASL-EASD-EASO — MASLD Clinical Practice Guidelines
• AASLD — New MASLD Nomenclature
• NIDDK — Diagnosis of NAFLD & NASH
• NHS — Non-alcoholic fatty liver disease